How Carestio was paid
$11.5M in total for fiscal 2026, as reported in the Summary Compensation Table. Equity awards are valued at grant, not at what they turned out to be worth.
Named executive officers
| Executive | Salary | Stock | Options | Incentive | Other | Total |
|---|---|---|---|---|---|---|
| Daniel A. CarestioPresident and CEO | $1,095,707 | $4,333,951 | $4,334,251 | $1,725,007 | $19,606 | $11,508,522 |
| Karen L. BurtonSenior Vice President and Chief Financial Officer | $530,762 | $1,042,037 | $1,111,148 | $491,493 | $16,977 | $3,192,417 |
| Michael J. TokichSenior Financial Advisor | $511,409 | $540,923 | $541,234 | $616,644 | $19,783 | $2,229,993 |
| J. Adam ZangerleSenior Vice President, General Counsel, and Company Secretary | $570,417 | $913,947 | $914,376 | $538,815 | $16,910 | $2,954,465 |
| Cary L. MajorsSenior Vice President and President, Healthcare | $537,115 | $711,010 | $711,242 | $473,535 | $17,522 | $2,450,424 |
| Mary Clare FraserSenior Vice President and Chief Human Resources Officer | $461,615 | $609,542 | $609,401 | $377,902 | $15,262 | $2,073,722 |
What changed and why
- 90.3%90.3% of CEO total compensation was variable in fiscal 2026.
- 125.1%125.1% of target annual incentive payout produced $1,725,007 for the CEO.
- 50%50% of CEO variable LTIP opportunity was delivered as premium-price stock options.
- 50%50% of CEO variable LTIP opportunity was delivered as restricted stock.
- 90.14%90.14% of votes supported named executive officer compensation in the 2025 say-on-pay vote.
- The committee continued the base salary, cash bonus, restricted stock, and stock option structure.
About this page
Figures are automated and can be wrong; check the filing for the exact numbers. Totals follow SEC rules, which value stock and option awards at grant. Read the DEF 14A proxy statement for footnotes and the compensation committee's full reasoning.